Review of current controversial issues in clinical trials

por Chow, Shein-Chung, Chow, Susan S, Pong, Annpey
Publicado 2021

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

por Liu, Jie, Pong, Annpey, Gallo, Silvina, Darekar, Amanda, Terra, Steven G.
Publicado 2019

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

por Gallo, Silvina, Calle, Roberto A., Terra, Steven G., Pong, Annpey, Tarasenko, Lisa, Raji, Annaswamy
Publicado 2020

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

por Heymsfield, Steven B., Raji, Annaswamy, Gallo, Silvina, Liu, Jie, Pong, Annpey, Hannachi, Hakima, Terra, Steven G.
Publicado 2020

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from...

por Weinstein, Cindy, Jordan, Karin, Green, Stuart, Khanani, Saleem, Beckford-Brathwaite, Elizabeth, Vallejos, Waldimir, Pong, Annpey, Noga, Stephen J., Rapoport, Bernardo L.
Publicado 2020

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus

por Liu, Jie, Patel, Shrita, Cater, Nilo B., Wu, Larry, Huyck, Susan, Terra, Steven G., Hickman, Anne, Darekar, Amanda, Pong, Annpey, Gantz, Ira
Publicado 2020

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV

por Dagogo‐Jack, Samuel, Cannon, Christopher P., Cherney, David Z. I., Cosentino, Francesco, Liu, Jie, Pong, Annpey, Gantz, Ira, Frederich, Robert, Mancuso, James P., Pratley, Richard E.
Publicado 2022

Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial

por Cherney, David Z.I., Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard E., Frederich, Robert, Maldonado, Mario, Liu, Chih-Chin, Pong, Annpey, Cannon, Christopher P.
Publicado 2022

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

por Cherney, David Z. I., Charbonnel, Bernard, Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Pong, Annpey, Cannon, Christopher P.
Publicado 2021

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

por Cherney, David Z. I., Charbonnel, Bernard, Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Pong, Annpey, Cannon, Christopher P.
Publicado 2022

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

por Cherney, David Z. I., Heerspink, Hiddo J. L., Frederich, Robert, Maldonado, Mario, Liu, Jie, Pong, Annpey, Xu, Zhi J., Patel, Shrita, Hickman, Anne, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado 2020

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus

por Segar, Matthew W., Kolkailah, Ahmed A., Frederich, Robert, Pong, Annpey, Cannon, Christopher P., Cosentino, Francesco, Dagogo‐Jack, Samuel, McGuire, Darren K., Pratley, Richard E., Liu, Chih‐Chin, Maldonado, Mario, Liu, Jie, Cater, Nilo B., Pandey, Ambarish, Cherney, David Z. I.
Publicado 2022